FibroGen Inc
FGEN11.310USD
-0.070-0.62%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
45.74MMarket Cap
LossP/E TTM
More Details of FibroGen Inc Company
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Company Info
Ticker SymbolFGEN
Company nameFibroGen Inc
IPO dateNov 14, 2014
CEOMr. Thane Wettig
Number of employees225
Security typeOrdinary Share
Fiscal year-endNov 14
Address350 Bay Street
CitySAN FRANCISCO
Stock exchangeLondon Stock Exchange
CountryUnited States of America
Postal code94133
Phone14159781200
Websitehttps://www.fibrogen.com/
Ticker SymbolFGEN
IPO dateNov 14, 2014
CEOMr. Thane Wettig
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thane Wettig
Mr. Thane Wettig
Chief Executive Officer, Director
Chief Executive Officer, Director
20.84K
-1.18%
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
16.10K
+393.71%
Mr. David Delucia
Mr. David Delucia
Chief Financial Officer
Chief Financial Officer
4.44K
-1.18%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
1.36K
+32.20%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
1.26K
+35.78%
Ms. Christine L. Chung
Ms. Christine L. Chung
Senior Vice President, China Operations
Senior Vice President, China Operations
--
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thane Wettig
Mr. Thane Wettig
Chief Executive Officer, Director
Chief Executive Officer, Director
20.84K
-1.18%
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
16.10K
+393.71%
Mr. David Delucia
Mr. David Delucia
Chief Financial Officer
Chief Financial Officer
4.44K
-1.18%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
1.36K
+32.20%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
1.26K
+35.78%
Ms. Christine L. Chung
Ms. Christine L. Chung
Senior Vice President, China Operations
Senior Vice President, China Operations
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
26.11M
88.16%
Europe
6.27M
21.17%
China
91.00K
0.31%
Japan - Related Party
-2.85M
-9.64%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 10
Updated: Wed, Sep 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.31%
The Vanguard Group, Inc.
4.40%
Acadian Asset Management LLC
3.44%
PRIMECAP Management Company
2.22%
BlackRock Institutional Trust Company, N.A.
2.08%
Other
79.55%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.31%
The Vanguard Group, Inc.
4.40%
Acadian Asset Management LLC
3.44%
PRIMECAP Management Company
2.22%
BlackRock Institutional Trust Company, N.A.
2.08%
Other
79.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
10.05%
Hedge Fund
9.32%
Investment Advisor/Hedge Fund
6.89%
Individual Investor
1.57%
Research Firm
0.22%
Family Office
0.01%
Other
71.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
277
1.30M
32.19%
-1.09M
2025Q1
349
1.54M
35.66%
-1.24M
2024Q4
354
38.15M
37.86%
-34.64M
2024Q3
363
47.69M
47.49%
-32.19M
2024Q2
377
57.63M
57.92%
-25.55M
2024Q1
379
62.46M
63.22%
-31.62M
2023Q4
378
71.59M
72.78%
-20.74M
2023Q3
393
71.13M
72.42%
-20.69M
2023Q2
420
83.19M
85.43%
-10.96M
2023Q1
450
83.25M
88.40%
-10.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
340.00K
8.41%
+68.00K
+25.00%
Mar 31, 2025
The Vanguard Group, Inc.
234.37K
5.8%
-714.00
-0.30%
Mar 31, 2025
Acadian Asset Management LLC
156.21K
3.87%
--
--
Mar 31, 2025
PRIMECAP Management Company
149.63K
3.7%
-35.01K
-18.96%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
93.06K
2.3%
-188.00
-0.20%
Mar 31, 2025
Marshall Wace LLP
88.50K
2.19%
+37.88K
+74.83%
Mar 31, 2025
Geode Capital Management, L.L.C.
43.18K
1.07%
+846.00
+2.00%
Mar 31, 2025
Hightower Advisors, LLC
16.18K
0.4%
+12.06K
+292.72%
Mar 31, 2025
Wettig (Thane)
21.10K
0.52%
+14.79K
+234.52%
Mar 31, 2025
Schoeneck (James A)
16.10K
0.4%
+12.84K
+393.71%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Proshares Ultra Russell 2000
0%
iShares Morningstar Small-Cap Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Global X Aging Population ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
iShares Morningstar Small-Cap ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Fidelity Enhanced Small Cap ETF
0%
View more
Proshares Ultra Russell 2000
Proportion0%
iShares Morningstar Small-Cap Value ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Global X Aging Population ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
